SMR 2024 | Exploring the role of personalized ctDNA monitoring in high-risk melanoma
Meghan Mooradian, MD, Massachusetts General Hospital, Boston, MA, shares results from a study (NCT06146920) exploring the potential role of circulating tumor DNA (ctDNA) monitoring for high-risk melanoma in 57 evaluable patients. Patients that were ctDNA positive at baseline and experienced major pathologic response demonstrated either clearance or a significant decline in ctDNA levels. The study highlights the prognostic value of personalized ctDNA monitoring for patients with advanced melanoma in a perioperative cohort and the utility of post-operative surveillance in the adjuvant cohort. This interview took place at the 21st International Congress of the Society for Melanoma Research (SMR) in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
